Drug: Rucaparib (Clovis Oncology)
Status: The therapy is being developed as monotherapy treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations, as detected by an FDA-approved test, who have been treated with two or more chemotherapy regimens.
FDA History: Rucaparib has been granted breakthrough therapy designation for this proposed indication (April 2015). A New Drug Application was submitted to the FDA (June